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KEYWORDS Summary Heart failure is a major public health problem. Heart failure with preserved systolic
Heart failure;
Diastolic heart
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Diastolic dysfunction;
function (HF-PSF) is a common form, which is difﬁcult to diagnose. Results of recent studies show
that HF-PSF has a poor prognosis, with an annual survival rate similar to that of heart failure
with left ventricular systolic dysfunction. Despite these ﬁndings, the therapeutic management
of HF-PSF is not clearly deﬁned. We will discuss in this review of the literature the current
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therapeutic management of HF-PSF, including the role of precipitating factors such as hyper-
tension, myocardial ischaemia and supraventricular arrhythmias, and the main results of
epidemiological registries and randomized controlled clinical trials in this disease. Only four
large therapeutic trials have assessed the impact of different classes of drugs (digoxin,
angiotensin II converting enzyme inhibitors, angiotensin II receptors type I blockers and beta-
blockers) on morbidity and mortality in HF-PSF. Results of these trials are disappointing. Apart
from the beta-blockers, the other three classes of drugs did not show beneﬁt on the outcome
of the disease. Moreover, the results of the beta-blocker trial are controversial as a mixed
population of heart failure with and without preserved systolic function was studied. Finally,
the current therapeutic management of patients with HF-PSF is still based on our pathophys-
iological knowledge: education, low salt diet, diuretics, slowing heart rate and controlling
triggering factors. Other large randomized controlled multicenter trials, which may help us in
the understanding of HF-PSP and its therapeutic management, are ongoing.
© 2008 Published by Elsevier Masson SAS.
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Résumé L’insufﬁsance cardiaque est un problème majeur de santé publique. L’insufﬁsance
cardiaque à fonction systolique préservée (IC-FSP) est une forme fréquente dont le diagnostic
est difﬁcile. Les résultats des études récentes montrent que le pronostic de l’IC-FSP est mauvais
avec une survie annuelle proche de celle de l’insufﬁsance cardiaque par dysfonction systolique
du ventricule gauche. Malgré ces données, la prise en charge thérapeutique de l’IC-FSP n’est
pas bien codiﬁée. Dans cet article, nous proposons une revue de la littérature sur cette prise en
charge thérapeutique. Nous nous sommes d’abord intéressés aux facteurs précipitant jouant un
rôle fréquent dans les épisodes de décompensation cardiaque : hypertension artérielle, ischémie
coronaire et troubles du rythme supraventriculaire. Puis, nous avons résumé la prise en charge
thérapeutique des patients atteints d’IC-FSP inclus dans les registres épidémiologiques. Enﬁn,
les données issues des études thérapeutiques randomisées et contrôlées, peu nombreuses dans
cette pathologie, sont analysées. Seules quatre études d’envergure ont évalué l’impact cli-
nique de certaines classes médicamenteuses : la digoxine, les antagonistes des récepteurs de
l’angiotensine II, les inhibiteurs de l’enzyme de conversion de l’angiotensine II et les bêtablo-
quants. Les résultats de ces études sont décevants. Hormis, les bêtabloquants, les trois autres
classes médicamenteuses n’ont pas démontré d’effets bénéﬁques sur l’évolution de la patholo-
gie. Pour les bêtabloquants, les résultats sont controversés, car la seule grande étude a inclus
une population mixte d’insufﬁsant cardiaque avec et sans fonction systolique préservée. Finale-
ment, en 2008, la prise en charge thérapeutique des patients ayant une IC-FSP reste basée sur
nos connaissances physiopathologiques : éducation, régime pauvre en sel, diurétiques, ralen-
tissement de la fréquence cardiaque et contrôle des facteurs déclenchant. D’autres études
multicentriques randomisées et contrôlées sont en cours qui nous permettront peut-être de
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eart failure with preserved systolic function (HF-PSF) is a
ommon, complex and severe disease. Its diagnosis is not
traightforward as it often affects elderly patients suffering
rom multiple diseases. In order to better understand HF-
SF, a French working group (the TACTIC group), proposed
diagnostic algorithm based on the patient’s clinical data
nd on the results of further investigations (Fig. 1) [1]. A
orking group of the European Society of Cardiology pub-
ished a similar process leading to the same conclusions [2].
n the present article, the TACTIC group has tried to review
rom the literature the current therapeutic management of
F-PSF. For this purpose, our conclusions were based on arti-
les published from 1985 to date and selected from medical
atabases using the following keywords: heart failure, dias-
olic heart failure, diastolic dysfunction, preserved ejection
raction, treatment.
In the absence of signiﬁcant results from random-
zed trials, the current treatment of HF-PSF is still
s
p
f
rmieux la prendre en charge.
sson SAS.
ased on our pathophysiological knowledge. The major
actor in this disease is the increase in left ventricu-
ar end-diastolic pressure. Aim of the treatment is to
educe the end-diastolic pressure and to avoid its sud-
en rise in certain circumstances. Kitzman et al. showed
hat ventricular ﬁlling pressures increase signiﬁcantly with
xercise in patients with isolated diastolic dysfunction
3].
Together with the speciﬁc treatment of HF-PSF, pre-
ipitating factors or concomitant (or causative) diseases
nvolved in HF-PSF must be corrected. These are hyper-
ension, myocardial ischaemia and supraventricular arrhyth-
ias. Isolated left ventricular hypertrophy (LVH) or LVH
omplicating hypertension predispose to the clinical expres-
ion of HF-PSF. Finally, HF-PSF generally occurs in the elderly
atient, who often has several comorbidities such as renal
ailure, which contribute to the symptoms and the deterio-
ation of the disease.
Treatment of heart failure with preserved systolic function
Figure 1. Diagnostic algorithm for heart failure with preserved
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than in those in whom LVH persists [28—31], but these tri-
als included small numbers of patients and do not establishsystolic function proposed by the TACTIC group (from reference [1]).
Management of precipitating or causative
factors
Role of hypertension and left ventricular
hypertrophy
Pathophysiological review
Factors predisposing to LVH in the hypertensive
patient
The prevalence of electrical LVH depends on several param-
eters:
• blood pressure level, particularly systolic [4,5];
• duration of hypertension and its control by antihyperten-
sive treatment [6];
• age and obesity.
A sodium rich diet [7] and alcohol consumption [8]
also predispose to the development of LVH in hypertensive
patients. LVH occurs more commonly in hypertensive men;
however, the direct inﬂuence of sex disappears when the
severity of hypertension and lifestyle are taken into account
[9,10]. Finally, genetic and ethnic factors are also involved
[11,12].
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athophysiological mechanisms of LVH in the hyper-
ensive patient
everal factors contribute to myocyte hypertrophy and
broblast proliferation.
Mechanical factors. Concentric LVH generally reﬂects
process of myocyte adaptation to elevated blood pressure
Laplace’s law), which becomes inappropriate and con-
ributes to the deterioration in left ventricular function.
n experimental models, genetically modiﬁed mice unable
o develop LVH when ventricular wall stress is increased by
pplying an aortic ring, exhibit less degree of heart failure
han control animals, which develop hypertrophy [13]. The
ole of arterial compliance and of central blood pressure in
he genesis of hypertensive LVH has also been clearly shown
y some authors as an important aetiological factor of HF-
SF and the main pathophysiological factor for episodes of
ecompensation [14].
Hormonal factors. The renin-angiotensin-aldesterone
ystem plays a central role in the development of LVH
15]. Many experimental studies have demonstrated the
ntitrophic role of angiotensin converting enzyme inhibitors
ACE) or angiotensin II receptor blockers (ARBs) [16—18].
ther hormonal factors are involved: catecholamines,
nsulin and growth hormone [19]. The antihypertensive
ffect of some drugs in the spontaneously hypertensive rat
s associated with a reduction in heart weight only if the
aemodynamic effect is combined with a reduction in cat-
cholergic activity (which was not true with direct acting
asodilators) [20].
esults of clinical trials
mpact of antihypertensive agents on LVH
esults of the ﬁrst studies on regression of LVH in
ypertension were difﬁcult to interpret because of some
ethodological limitations [21,22]. The results of recent
omparative trials with good methodological quality [23]
artly contradict those of meta-analyses, which mostly con-
luded that ACE and ARBs were superior to other drugs
24]. The Prospective Randomized Enalapril Study Evaluat-
ng Regression of Ventricular Enlargement (PRESERVE) trial
howed no difference between enalapril and nifedipine [25].
he Left Ventricular hypertrophy regression Indapamide
ersus Enalapril (LIVE) trial [26], which used a rigorous
ethodology, with a sufﬁciently large number of patients
200 patients per group), showed indapamide to be more
ffective than enalapril on reducing left ventricular mass at
ne year, with a comparable antihypertensive effect. The
argest LVH regression trial is the Losartan Intervention For
ndpoint reduction in hypertension (LIFE) trial [27], which
howed that, for a similar blood pressure control, losartan
together with a diuretic in 90% of cases) produced a greater
VH regression than atenolol (combined with a diuretic in the
ame proportion of patients).
onsequences of LVH regression on prognosis
he incidence of cardiovascular complications appears to
e lower in patients whose LVH had regressed on treatmenthether there was a parallel reduction in left ventricu-
ar mass and in cardiovascular risk. The lower incidence of
troke with losartan in the LIFE trial was associated with a
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reater LVH regression [32,33], although this difference may
e largely explained by a lower decrease in central blood
ressure by atenolol, as clearly shown in the Conduit Artery
unction Evaluation study (CAFE) trial [34].
ole of bilateral renal artery stenosis
econdary hyperaldosteronism and volume overload,
elated to a decrease of natriuresis, in case of signiﬁcant
ilateral renal artery stenosis could explain the clinical
resentation of HF-PSF and particularly the recurrent
‘ﬂash’’ acute pulmonary oedema. Revascularization in
his situation can prevent the recurrence of heart failure
ecompensation [35,36]. This justiﬁes to perform a renal
rtery Doppler study, particularly if predisposing factors
or renal stenosis are present: severe systolic—diastolic
ypertension resistant to antihypertensive treatments,
ge greater than 70 years old, multiple vascular lesions,
enal insufﬁciency, signiﬁcant increase in plasma creatinine
fter ACE or ARBs introduction. At the opposite, the role
f a unilateral renal stenosis in HF-PSF decompensation is
till discussed and angioplasty has not been shown to be
eneﬁcial in this situation.
ole of myocardial ischaemia
hysiological relationship between ischaemia and
F-PSF
n order to examine the relationship between left ventric-
lar diastolic dysfunction and myocardial ischaemia, two
uestions need to be answered:
is repeated or chronic myocardial ischaemia a factor
which initiates or predisposes to diastolic dysfunction?
can an acute ischaemic episode be a factor that initiates
or predisposes to heart failure in a patient with diastolic
dysfunction?
In answer to the ﬁrst question, we have to keep in mind
hat left ventricular relaxation requires the active trans-
ort of calcium into the sarcoplasmic reticulum, enabling
he dissociation of actin—myosin bridges. As a result of
ypoxia, which inhibits this dissociation process, ischaemia
an impaired active relaxation [37,38]. In addition, by
redisposing to cell necrosis and the development of inter-
titial ﬁbrosis, ischaemia contributes to the deterioration in
eft ventricular structure and diastolic function. Ischaemia
an therefore reduce passive left ventricular compliance.
yocardial ischemia could also be related to microcircula-
ory abnormalities, as found in hypertension and in diabetes
ellitus [39].
In order to answer the second question, many years ago,
cute myocardial ischaemia was shown to be involved in
he development of heart failure [40,41], and this is still
current issue [42,43]. In 1987, a study demonstrated in 32
atients that all the echocardiographic diastolic parameters
ere impaired in the ﬁrst 15 s after coronary artery occlusion
41]. In 2004, in a small study including 18 patients hospital-
zed for heart failure with left ventricular ejection fraction
LVEF) greater or equal to 50%, a signiﬁcant coronary artery
isease was found by coronary angiography in 39% of patients
nd in 25% of cases, heart failure was associated with an
pisode of myocardial ischaemia [43]. Finally, the extend of
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oronary disease is associated with an increase in mortality
n patients with HF-PSF: ﬁndings from the coronary artery
urgery study (CASS) showed that in patients with HF-PSF,
he six-year mortality rate was 8% in the absence of coro-
ary artery disease, compared to 17% in the presence of a
igniﬁcant single or double vessel disease and 32% in case of
riple vessel disease [44].
There are therefore arguments indicating that myocar-
ial ischaemia can contribute to diastolic dysfunction and
ay be the cause of heart failure in a patient with diastolic
ysfunction.
reatment of ischaemia and prevention of HF-PSF
nd episodes of heart failure
wo questions must be answered to examine the relationship
etween anti-ischaemic treatment and prognosis of HF-PSF:
does anti-ischaemic treatment (pharmacological or revas-
cularization) in a patient without cardiac dysfunction
reduces the risk of HF-PSF?
does anti-ischaemic treatment (pharmacological or by
revascularization) prevent heart failure decompensation
in a patient with HF-PSF?
To the best of our knowledge, no clinical trials have
nswered to these two questions. We just have substud-
es of different clinical trials and/or meta-analyses without
ny information about the type of heart failure assessed.
hile the treatment of coronary risk factors, particularly
he treatment of hypertension, reduces the risk of heart fail-
re, anti-ischaemic treatment does not appear to reduce the
ncidence of heart failure [45,46]. In the meta-analysis of
he Blood Pressure Lowering Treatment Trialists’ collabora-
ion (BPLTT) [46], beta-blockers were not superior to ACE in
reventing heart failure. However, calcium channel block-
rs appeared to be less effective than ACE, but also less
ffective than diuretics and beta-blockers in preventing the
evelopment of heart failure.
In the Occluded Artery Trial (OAT), desocclusion of a coro-
ary artery by angioplasty did not reduce the risk of heart
ailure [47]. Furthermore, angioplasty of an occluded artery
ad no effect on prognosis, whether or not the patients had
revious heart failure and whether or not they had LVEF less
han 50%.
A study published in 2000 examined the ﬁndings from
6 patients hospitalized for rapidly resolving acute pul-
onary oedema (‘‘ﬂash’’ oedema) [45]. Twenty-seven of
hese patients (58%) had LVEF greater than 40%, 38 (82%)
nderwent coronary angiography and among these, 33 (86%)
ad a signiﬁcant coronary artery disease. Nineteen of these
3 patients underwent bypass surgery and eight a coronary
ngioplasty. During the three-year of the follow-up period,
ulmonary oedema recurred in half of the patients, and
n nine patients (47%) of the 19 who were revascularized.
espite its major limitations (small number of patients and
ack of randomization), this study suggests that coronary
evascularization has no preventive effect on the devel-
pment of pulmonary oedema in patients with preserved
ystolic function and a past history of pulmonary oedema.
Finally, the ACC/AHA 2001 guidelines for the manage-
ent of HF-PSF state that ‘‘coronary revascularization is
ecommended in patients with coronary artery disease in
hom symptomatic or demonstrable myocardial ischaemia
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is judged to have an adverse effect on diastolic function’’
although with a level of evidence of C [48]. This proposal
is based on pathophysiological reasoning but not on clinical
evidence. In 2005, the European and American guidelines
for the management of heart failure both stated that there
was a strong evidence to perform coronary revascularization
only to patients with angina and not to patients with asymp-
tomatic coronary disease [49,50]. They did not recommend
coronary revascularization in order to improve ventricular
function or to reduce symptoms of heart failure [51].
Role of supraventricular arrhythmias
Supraventricular arrhythmias are considered to have an
adverse effect in HF-PSF. Tachycardia, which reduces the
duration of diastole, and the loss of atrial systole con-
siderably decrease cardiac output. LVH increases these
abnormalities. In experimental studies in dogs, sinus tachy-
cardia in the presence of LVH rapidly increases left atrial
pressure [52]. The theoretical treatment of choice to control
heart rate is beta-blockers, which also reduce myocardial
ischaemia and blood pressure. Non-dihydropyridine calcium
blockers and/or digoxin, particularly in case of atrial ﬁbrilla-
tion, are an alternative to beta-blockers. The ideal situation
is to obtain a heart rate close to 70 per minute and in
any case lower than 90 per minute. Atrial ventricular node
ablation with pacemaker implantation is rarely required.
Atrial ﬁbrillation ablation may be useful in case of recurrent
heart failure decompensations. Finally, the role of ivabra-
dine in controlling heart rate in patients with sinus rhythm
is unknown in HF-PSF.
Other triggering factors
Heart failure decompensation may be promoted by extrac-
ardiac factors such as non compliance to the low sodium
diet or to medical treatment, intake of non-recommended
drugs (particularly non-steroidal anti-inﬂammatory drugs,
rich sodium drugs, etc.), pulmonary infection or any other
infection and anemia. These extracardiac factors are not
speciﬁc to HF-PSF but also affect heart failure with systolic
dysfunction.
Data from registers and controlled trials
on the pharmacological management of
HF-PSF
Speciﬁc features of HF-PSF
As described in the introduction, the treatment of HF-PSF is
currently based on our pathophysiological knowledge. The
main goal of the treatment is to reduce the left ventricular
end-diastolic pressure.
By avoiding salt and water retention, diuretics are the
treatment of choice for this disease. However, as in heart
failure with systolic dysfunction, no study has assessed their
beneﬁt in HF-PSF. With nitrates, diuretics are effective in the
management of acute episodes. In chronic stable patients,
the minimal doses of diuretics will be prescribed, partic-
ularly in the elderly, in order to control symptoms and to
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educe the risk of dehydration. In HP-PSP, the adaptive possi-
ility of the heart is decreased, related to a steeper diastolic
ressure—volume curve. Minor changes in volume are asso-
iated with large changes in pressure (a moderate increase
n volume increases the risk of decompensation, and in con-
rast, a small reduction in ventricular volume predisposes to
ypotension).
Heart rate plays an important role in the increase of
iastolic pressures. Alongside diuretics, nitrates and beta-
lockers, calcium channel blockers slowing heart rate can
e used. Finally, theoretically, renin-angiotensin system
nhibitors are useful in the management of these patients:
hey control blood pressure, reduce left ventricular mass
nd may improve diastolic function [53].
pidemiological studies
everal observational epidemiological studies have exam-
ned the numbers of prescriptions of different classes of
rugs. In some of these studies, the authors examine the
mpact of various drugs on morbidity and mortality. These
tudies are not randomized trials and all of these analyses
ere conducted retrospectively. Nevertheless, they provide
seful information on the therapeutic management of HF-
SF.
An important initial ﬁnding from these registries is the
elatively limited use of LVEF measurement in patients
ospitalized for acute heart failure. In American studies
54—57], LVEF measurement was performed in approx-
mately 50—60% of the patients, at the exception of
ne study, the Organized Program to Initiate Lifesav-
ng Treatment in Hospitalized Patients With Heart Failure
OPTIMIZE-HF) trial [58] where LVEF was measured in 85% of
he patients. In Europe, LVEF is measured in almost 80% of
atients [59,60].
rescription rates for the different classes of drugs
rescription rates of the different classes of drugs from
ome epidemiological studies are summarized in Table 1.
ost of these studies involved patients admitted in hospitals
or heart failure decompensation. Shamagian et al. divided
heir Spanish population into three groups depending on the
ear of hospitalization [60]. The study, from the Cardiovas-
ular Health Study, examined the general population over
5 years old with ambulatory HF-PSF. In the Berry study,
iuretic and ACE prescription rates should be interpreted
ith caution as these drugs were one of the inclusion criteria
59].
In some studies, the authors compared the type of man-
gement according to the severity of LV dysfunction. In the
anagement to Improve Survival in Congestive Heart Fail-
re (MISCHF) register, the 1291 patients were divided into
hree subgroups depending on LVEF function: less or equal
o 39%, 40 to 50%, and greater than 50% [55]. In the major-
ty of cases, ACE were being prescribed more commonly int discharge from hospital. The doses of ACE were also
igher in systolic dysfunction [55]. Similar results were found
n the EuroHeart Failure survey [62,63]. The same ﬁnding
lso applies to beta-blockers in the most recent analyses
57,63].
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Table 1 Prescription rates of different classes of drugs in epidemiological studies.
n Date LVEF (%) Diur (%) ACE (%) ARBs (%) BB (%) Spir (%) Ca-B (%) Digo (%)
CHS 170 1989—1993 ≥ 55 59 25 17 31 41
REP 91 59 1991 ≥ 50 78 31 19 24 27
Alabama 238 1994 ≥ 40 30 31 47
MISCHF 312 1995—1997 ≥ 50 59 29 23 39 30
76 45 19 43 36
Smith et al. 200 1996—1998 ≥ 40 79 34 19 50 30
Berry 130 2000 ≥ 40 95 65 38 12 24 23
Spanish 147 1991—1996 ≥ 50 64 42 0 12 10 18 39
Study 109 1997—1999 69 55 5 12 5 30 22
186 2000—2001 64 49 6 28 12 36 16
EuroHeart 3,148 2000—2001 ≥ 40 85 58 4 39 17 28 31
Failure
Dobre 443 2000—2005 ≥ 40 88 66 12 51 41 15 22
FOCALE 245 ? ≥ 45 67 53 16 34 16 12 19
REP 03 306 2003—2005 ≥ 50 24 17 21
71 51 63
ADHERE 26,322 2004 ≥ 40 65 36 13 46 5 19
80 47 13 52 11 21
LVEF: left ventricular ejection fraction; Diur: diuretics; ACE: angiotensin II converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; BB: beta-blockers; Spir: spironolactone:
CaB: calcium channel blockers; Digo: digoxin.
For the trials by Smith et al., Berry et al., Dobre et al. and the Spanish trial, treatment was at discharge from hospital. The second line in the MISCHG, REP 03 and ADHERE studies is
treatment at discharge from hospital. The FOCALE trial randomized ambulatory patients over 65 years old with an ECG and echocardiogram at inclusion.
CHS, [61]; REP91, [54]; Alabama, [65]; MISCH, [55]; Smith et al., [82]; Berry et al., [59]; Spanish trial, [60]; EuroHeart Failure Survey, [63]; Dobre et al., [66]; FOCALE, [81]; REP 03, [64];
ADHERE, [57].
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In other studies, prescription rates of different drugs
before hospitalization and at discharge have been exam-
ined [55,57,64]. Diuretics were the most widely prescribed
drugs in these studies, followed by the ACE, with an increase
in their prescription rates during the hospitalization. How-
ever, we do not know whether this approach was guided by
blood pressure level. The prescribing rate of beta-blockers
also appears to increase in the studies conducted after 2000
whereas digoxin prescription decreased, from 40% in the
1990s to 20% after 2000. Prescription rate of calcium chan-
nel blockers remains relatively stable with no information
available about the type of calcium blocker (vasodilators or
bradycardiac agents).
Relationship between treatments and
morbidity—mortality rates
Because of some contradictory results of different retro-
spective studies from registries, it is difﬁcult to draw any
conclusions.
An analysis of a population from the American MEDICARE
system including 1091 patients over 65 years old, hospital-
ized in 1994 for heart failure did not show any relationship
between the prescription of ACE and four-year survival
in the 238 patients with LVEF greater and equal to 40%
[65].
In the MISCHF register, ACE prescription was associated
with a shorter length of hospitalization and a 60% reduc-
tion in the six months mortality rate in patients with LVEF
between 40 and 49%. Conversely, prescription of ACE in the
subgroup of patients with LVEF greater or equal to 50% was
associated with a 30% non-signiﬁcant decrease in morbid-
ity and mortality [55]. The power of this analysis is limited
by the small number of patients per subgroups (less than
200).
In the Spanish study, authors compared mortality of their
patients admitted for heart failure decompensation with
a separate analysis over three different inclusion periods
[60]. Annual mortality was similar during the three periods,
between 9 to 12%. By multivariate analysis, the prescription
of ACE or of an ARBs was associated with a greater survival
rate (36% mortality reduction). On the other hand, digoxin
was associated with a 40% signiﬁcant increase in mortality.
In the Dutch study [66], prescription of beta-blockers was
associated with a signiﬁcant reduction in mortality, with an
adjusted relative risk of 0.57 [0.37—0.88, p = 0.01], with a
dose effect. It is interesting to note that in this study, digoxin
prescription was also associated with an excess mortality
(adjusted RR = 1.58 [1.006—2.47, p = 0.05]).
The ACE and beta-blockers were also found to have a
beneﬁcial effect in the EuroHeart Failure Study [63]. After
12-week of follow-up, prescription of ACE and of beta-
blockers were associated with a 45% (RR = 0.55 [0.43—0.71])
and with a 39% (RR = 0.61 [0.48—0.77]) reduction in total
mortality, respectively.
Clinical trialsSmall studies and retrospective analyses
A few small studies (with less than 400 patients) have
assessed the effect of different classes of treatment in HF-
PSF.
u
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The open study by Aronow et al. assessed the effect of
beta-blocker, propanolol (90mg/d), on prognosis in 158
atients, aged 81± 8 years old, in class II-III NYHA with
VEF greater or equal to 40% and a history of myocardial
nfarction [67]. All the patients were receiving diuretics
nd ACE for at least two months. Total mortality after 32-
onths of follow-up was reduced by 35% with propanolol
44 deaths compared to 60, p = 0.007) and total mortality
nd non-fatal myocardial infarction were reduced by 37%
p = 0.002).
The Survival of Myocardial Infarction Long-Term Evalu-
tion study (SMILE-ISCHEMIA study) examined zofenopril in
03 patients admitted with myocardial infarction and LVEF
reater than 40% [68]. The primary objective of the study
as to examine the effect of zofenopril on the extent of
yocardial ischemic burden (studied by a 24 h Holter moni-
oring and by an exercise test) after six months of treatment.
he study demonstrated a signiﬁcant reduction of the pri-
ary objective with zofenopril. There were only two deaths
uring the follow-up period and heart failure developed or
orsened in 12 patients: all except for one of these were on
lacebo.
A retrospective analysis of the European Trial on Reduc-
ion of Cardiac Events with perindopril in stable coronary
rtery disease study (EUROPA) was conducted in patients
ith LVEF greater than 40% [69]. The EUROPA study was
double-blind, randomized, placebo controlled trial of an
CE, perindopril (8mg/d), in 12,218 patients with coronary
rtery disease but without clinical evidence of heart failure.
VEF was measured in 58% of the population, of whom 6,878
atients (56%) had LVEF greater than 40%. Perindopril sig-
iﬁcantly reduced the incidence of the primary end point
cardiovascular mortality, non-fatal myocardial infarction
nd resuscitated sudden death) from 9.8 to 8.3% (RR = 0.84
0.77—0.98]).
arge-scale trials
our randomized, placebo-controlled, multicenter trials
ave examined the effects of different pharmacological
reatments in HF-PSF: the DIG, CHARM-preserved, PEP-CHF
nd SENIORS trials.
The major therapeutic characteristics of these trials are
ummarized in Table 2. Diuretics were still the most com-
only prescribed class of drugs, followed by beta- blockers
n the two most recent studies. ACE were widely pre-
cribed in the DIG trial and digoxin prescription was variable,
etween 12 and 40%, in the three other trials.
igitalis Intervention Group (DIG trial)
he DIG trial can be considered to be the ﬁrst random-
zed multicenter trial in HF-PSF. A subgroup of 988 North
merican patients with a LVEF greater than 45% was ran-
omized to receive digoxin (492 patients) or placebo (496
atients). Digoxin had no impact on total or cardiovascular
ortality, mortality from heart failure or on the majorityre were signiﬁcantly reduced with digoxin but only after
wo-year of follow-up and this difference was not signiﬁcant
t the end of the trial. There was a trend towards more
ospitalization for unstable angina in patients on digoxin
70].
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Table 2 Prescription rates of different classes of drugs in the 4 randomized trials in HF-PSF.
n Date LVEF (%) Diur (%) ACE (%) ARBs (%) BB (%) Spir (%) CaB (%) Digo (%)
DIG 988 1991—1993 ≥ 45 76 86 8
CHARM 3,023 1999—2000 ≥ 40 75 19 56 12 32 28
SENIORS 2,135 2000—2002 86 83 7 28 11 40
PEP-CHF 850 2000—2003 ≥ 40 46 55 10 33 12
55a
LVEF: left ventricular ejection fraction; Diur: diuretics; ACE: angiotensin II converting enzyme inhibitors; ARBs: angiotensin II receptor
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andesartan in Heart Failure Assessment of Reduction
n Mortality and Morbidity-Preserved study (CHARM-
reserved study)
his is to date the largest trial in terms of number of
atients, which examine the effects of an ARBs, the can-
esartan in HF-PSF [71]. CHARM-preserved trial included
023 patients older than 18 years, with NYHA class II-IV
linical heart failure who had been hospitalized at least
nce for a cardiac cause and had an LVEF greater than 40%.
atients were randomized double-blind against placebo. The
rimary objective was to examine the effect of candesartan
n cardiovascular mortality and hospitalizations for heart
ailure. After 36.6-months of follow-up, candesartan had not
educed the incidence of the primary end point (22% versus
4% with a 11% non-signiﬁcant reduction on candesartan).
andesartan had no impact on the different secondary end
oints (hospitalization for heart failure, myocardial infarc-
ion, stroke or coronary revascularization). The average
ose of candesartan at six months was 25mg/d. There were
igniﬁcantly more adverse effects on candesartan than on
lacebo: more hypotension (2.4% versus 1.1%), more hyper-
alaemia (1.5% versus 0.6%) and a greater rise in serum
reatinine (4.8% versus 2.4%).
Despite this statistically negative result, the CHARM trial
hows that a large scale randomized trial can be conducted
n this complex disease. This study opened the way for new
rials in HF-PSF.
tudy of the Effect of Nebivolol Intervention on Out-
omes and Rehospitalization in Seniors With Heart
ailure trial (SENIORS trial)
he SENIORS trial cannot be considered to be a speciﬁc
rial of HF-PSF because HF-PSF patients only represented a
ubgroup of the total population and because the LVEF cut-
ff value deﬁning HF-PSF was unusually low (LVEF greater
han 35%) [72]. The aim of the trial was to examine the
ffect of a beta-blocker, nebivolol, in 2135 patients over
0 years, who had either been hospitalized within the pre-
ious year for heart failure or in whom an LVEF of less or
qual to 35% had been found within the previous six months.
he major end-point was total mortality and hospitaliza-
ions for a cardiovascular cause. After a follow-up period
f 21 months, nebivolol produced a signiﬁcant 14% reduc-
ion in the incidence of the primary end-point (31.1% versus
5.3%, p = 0.04). Median LVEF was 34%, although only 20% of
he population had an LVEF greater than 40%. The effect of
ebivolol on the primary end-point was similar whether the
VEF was over or under 35%.
S
y
T
sl blockers; Digo: digoxin.
erindopril in Elderly People — Congestive Heart Fail-
re trial (PEP-CHF)
he PEP-CHF trial examined the effect of an ACE, perindo-
ril 4mg/d, on morbidity and mortality in elderly patients
ollowed up for HF-PSF [73]. The inclusion criteria were
ge greater or equal to 70 years, heart failure treated with
iuretics, with a LVEF greater than 40%. In addition, three
ut of nine clinical criteria for heart failure and two out
f four echocardiographic criteria for diastolic dysfunction
ere required. The average age was 75 years and 55% of
he patients were women, 79% were hypertensive and 26%
ad a past history of myocardial infarction. The primary
nd-point was total mortality and hospitalizations for heart
ailure at one year. The trial showed a non-signiﬁcant impact
f perindopril on the primary end point. The annual event
ate was 12.2% in the perindopril subgroup and 13.2% in the
lacebo subgroup. At the end of the trial, event rates were
3.6 and 25.1%, respectively. Similar results were found
ith all the secondary end points: total or cardiovascular
ortality, hospitalizations for heart failure, duration of hos-
italizations, increase in treatment.
These results are difﬁcult to interpret because of numer-
us problems. The inclusion period, as well as the follow-up
eriod, were extended in order to obtain a sufﬁcient number
f events. The drop-out rate was relatively high, 40% in the
erindopril group and 36% in the placebo group. Open label
CE was prescribed in 35% of the patients in the perindopril
rm and in 37% in the placebo arm.
In summary, these trials did not show any signiﬁcant
ffect of different classes of drugs studies, digoxin, ACE or
RBs, except for a beta-blocker (nebivolol) in a non-speciﬁc
F-PSF study.
Two other randomized trials are ongoing: one, the Irbe-
artan in Heart Failure With Preserved Systolic Function trial
I-PRESERVE) [74] is assessing irbesartan and the other, the
rial of aldosterone antagonist therapy in adults with pre-
erved ejection fraction congestive heart failure (TOPCAT
rial) is assessing an aldosterone receptor blocker, spirono-
actone. The results of these two trials will perhaps enable
s to improve the management of patients suffering from
F-PSF.pecial features of elderly patients over 80
ears old
he prevalence of HF-PSF increases with age. The diagno-
is in octogenarians is often difﬁcult because of atypical
c
e
i
i
m
c
t
i
u
o
o
a
t
P
p
f
t
l
b
t
o
p
a
K
a
C
T
ﬁ
t
m
o
m
c
o
o
t
a
RTreatment of heart failure with preserved systolic function
symptoms [75]. In addition, some non-speciﬁc ‘‘geriatric’’
signs (asthenia, confusion, behavioral disorders, fall, loss
of independence) can also be the only clinical feature of
heart failure, which is responsible for a delay in diagnosis
and treatment. The clinical presentation is even more atyp-
ical and the prognosis even poorer if the heart failure occurs
in frail patients with several comorbidities. Epidemiological
data from a register of 86,094 institutionalized 85-year-old
patients with heart failure [76] indicate that one third of
the patients had at least six comorbidities in addition to
heart failure, with a higher prevalence of cognitive disor-
ders (57% of cases). In the Euro Heart Failure Survey I [77],
infection was present in 42% of patients over 80 years old,
confusion in 23%, anemia in 23% and severe renal failure
(creatinine clearance less than 30ml/min) in 15%. The pres-
ence of these comorbidities implies geriatric management in
order to identify markers of ‘‘fragility’’ in the elderly (cogni-
tive problems, walking disorders, depression, malnutrition,
social isolation, loss of independence etc.) [78].
Cardiovascular disease is more serious in the elderly. In
the Euro Heart Failure Survey I registry, total mortality at
12 weeks in patients with HF-PSF was signiﬁcantly higher
in octogenarians (average age 85 years old) compared to
younger patients (average age 69 years old) (17% versus 7%,
p < 0.0001) [77]. The excess mortality was due to both car-
diovascular and non-cardiovascular causes. Because of this,
it may be useful to consider the best end-points to be used in
this population in future clinical trials: mortality, cardiovas-
cular events, rehospitalisation, quality of life? In practice,
the therapeutic management for each patient must be based
not on actual age but on an individual assessment taking
into account the ‘‘geriatric evaluation’’ of the elderly (life
expectancy, quality of life, comorbidities, frailty, iatrogenic
risk, etc.) [78].
Educational program
Few studies have assessed the effect of multidisciplinary
management in patients with HF-PSF. Interpretation of the
results of theses studies are therefore difﬁcult but the effect
of multidisciplinary management appears to be less effec-
tive than in patients with systolic dysfunction.
It is possible that studies demonstrating a beneﬁt of
multidisciplinary management in terms of morbidity and
mortality have included patients with HP-FSP, although no
analysis by type of dysfunction was available until the pub-
lication by Galbreath et al. [79]. These authors randomized
1069 patients with heart failure and compared multidis-
ciplinary follow-up with telephone calls and education to
conventional follow up for 18 months. Seventy per cent of
patients had systolic dysfunction and 30% had HF-PSF. This
study demonstrated a signiﬁcant reduction in mortality and
cardiovascular events in the group of patients with systolic
dysfunction whereas no signiﬁcant effect was found in the
subgroup of patients with HF-PSF. Multidisciplinary manage-
ment in this study had little impact on blood pressure and
this subgroup of patients appeared to be at lower risk.In terms of effect on quality of life, this may be more
signiﬁcant although again there are insufﬁcient studies
available. One study conducted in 32 women with NYHA
class II or III and LVEF greater than 45%, randomized to 12
weeks of mild to moderate regular physical exercise asso-369
iated with therapeutic education compared to therapeutic
ducation alone showed signiﬁcant improvement in walk-
ng tolerance, quality of life and depression indices in the
ntervention group [80].
Therapeutic education and multidisciplinary manage-
ent in patients with HF-PSF is probably more useful in
ontrolling etiological and precipitating factors than in
erms of preventing decompensation and reducing mortal-
ty. Therefore, the inﬂuence of therapeutic education is
ndoubtedly involved in the beginning of the disease. Deteri-
ration in diastolic function often precedes the development
f the initial symptoms by several years and early diagnosis
nd treatment of these abnormalities are essential in order
o prevent irreversible damages. Primary prevention of HF-
SF requires smoking cessation and drastic control of blood
ressure, hypercholesterolaemia and all other risk factors
or coronary artery disease.
As for systolic dysfunction, changes in lifestyle are essen-
ial and must be combined with an appropriate diet with
ow sodium and alcohol intake and physical activity must
e maintained. Weight monitoring and control of conges-
ive signs are important but often difﬁcult as exacerbations
f left heart failure are usually sudden and more rarely
receded by warning signs (reduced walking tolerance,
rrhythmia, increase of blood pressure, infection etc.).
nowledge of these warning signs however remains essential
nd patients must be educated about them.
onclusions
he therapeutic management of patients with HF-PSF is dif-
cult. The lack of clear results from the few randomized
rials in this disease does not help us in its management. This
anagement is based on our pathophysiology knowledge
f HF-PSF which is multifactorial, involving hypertension,
yocardial ischaemia, intrinsic myocardial damage and con-
omitant diseases (diabetes, renal failure). In the absence
f signiﬁcant results of large therapeutic trials, treatment
f HF-PSF is therefore based on patient education and con-
rol of salt and water retention, blood pressure, heart rate
nd episodes of myocardial ischaemia.
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